John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 54,139 shares at $7.44 ($403K) on 2022-03-02, disclosed to the SEC on 2022-03-03.
Open-market sale of $403k FUSN by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.37 | 847 | $6K | 1.6% |
| 2 | $7.44 | 26,546 | $198K | 49.0% |
| 3 | $7.44 | 26,546 | $198K | 49.0% |
| 4 | $7.28 | 200 | $1K | 0.4% |
| Total | $7.44 avg | 54,139 | $403K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |